ʻO ke koho makemake ʻia no ka hoʻokele ʻana i ka nausea a me ka luaʻi i hoʻoulu ʻia e ka chemotherapy (CINV). ʻO ka nausea a me ka luaʻi i hoʻoulu ʻia e ka chemotherapy (CINV) kekahi o nā hopena ʻino i makaʻu nui ʻia i waena o nā poʻe maʻi e mālama ʻia ana i ka maʻi kanesa, e hoʻopilikia nui ana i ka mālama ʻana i ka mālama ʻana a me ke ʻano o ke ola. Ma ke ʻano he hanauna hou o nā antagonists receptor NK1, ʻo Fosaprepitant Dimeglumine, me kāna mau waiwai pharmacological o ke koho kiʻekiʻe a me ka pilina kiʻekiʻe, hiki ke ālai ikaika i ke ala hōʻailona luaʻi i hoʻopili ʻia e ka mea P.
Ua hōʻoia nā ʻikepili lapaʻau e hōʻike ana kēia huahana i nā hopena kaohi maikaʻi loa ma ka nausea a me ka luaʻi koke a lohi i hoʻokumu ʻia e ka chemotherapy emetogenic kiʻekiʻe (HEC) a me ka chemotherapy emetogenic moderately (MEC). Hiki i ka hoʻokele hoʻokahi ke hoʻokō i ka antiemesis hana lōʻihi me ka hoʻomanawanui maikaʻi. Ke hui pū ʻia me nā antagonists receptor 5-HT3 a me dexamethasone, kūkulu ia i kahi ʻōnaehana pale CINV piha a piha.
Mai ka maʻalahi o ka hoʻokele ʻana a hiki i ke kūpaʻa o ka pono, hāʻawi ʻo Fosaprepitant Dimeglumine i kahi koho maikaʻi aʻe no ka hana lapaʻau, e kōkua ana i nā maʻi e hele ma o ke kaʻina hana chemotherapy me ka maʻalahi a me ka hoʻolilo ʻana i ka mālama ʻana i ka maʻi kanesa i mea aloha.
Ka manawa hoʻouna: Dec-09-2025
